ACM
RARE icon

Atika Capital Management’s Ultragenyx Pharmaceutical RARE Stock Holding History

Atika Capital Management’s Portfolio RARE Stock Details RARE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-500
Closed -$1.5M – 106
2025
Q3 		$1.5M Buy
+500
New +$15K 0.12% 80

Other funds holding RARE

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
Sands Capital Management
Sands Capital Management Arlington, Virginia $25.5B AUM 26.46% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Atika Capital Management's RARE Position: Q4 2021 in Review

Atika Capital Management sold out of Ultragenyx Pharmaceutical (RARE) in Q4 2021, closing a stake of 39,700 shares — an estimated $3.58M sold.

Atika Capital Management first reported a position in RARE in Q2 2015 and held it in 10 quarters. The position peaked at $12.3M in Q4 2020. 235 funds tracked by Wall St. Rank hold RARE as of Q4 2021.

  • Atika Capital Management reported no remaining Ultragenyx Pharmaceutical position as of Q4 2021 after selling out during the quarter.
  • Atika Capital Management sold 39,700 Ultragenyx Pharmaceutical shares in Q4 2021, an estimated $3.58M.
  • Atika Capital Management first reported a position in Ultragenyx Pharmaceutical in Q2 2015 and held it in 10 quarters.
  • Atika Capital Management's Ultragenyx Pharmaceutical position peaked at $12.3M in Q4 2020.
  • 235 funds tracked by Wall St. Rank held Ultragenyx Pharmaceutical as of Q4 2021.

Based on Atika Capital Management's 13F filing for Q4 2021, filed 11 Feb 2022.